GlassScriptPhysician profile
Howard A Rubin
NPI 1558544775
$19,049.14
in general payments reported to CMS, 2019-2025
41 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $7,713 · 2021: $3,564 · 2022: $922 · 2023: $1,697 · 2024: $2,103 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,473 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $208 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,473.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $208.12 |
| Education | $112.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $10,793.05 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Abbvie INC. | $883.49 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Regeneron Healthcare Solutions, INC. | $711.40 | 2019-2025 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $698.17 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $647.96 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $534.90 | 2022-2025 | |
| Lilly USA, LLC | $525.05 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $441.57 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $422.18 | 2021-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $315.44 | 2020-2025 | |
| Janssen Biotech, INC. | $296.79 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $289.80 | 2019-2024 | Adbry |
| Almirall LLC | $287.17 | 2019-2022 | |
| Allergan, INC. | $233.16 | 2019-2022 | |
| Kerecis Limited | $232.78 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.